Mark S. Sands, Ph.D.

Reviews & Book Chapters

• Sands MS, Davidson BL
  Gene therapy for lysosomal storage diseases.
  Mol Ther 2006 May;13(5):839-49
• Sands MS, Nolta JA, Bauer G, Ferkol T
  Pre-clinical basis for gene therapy studies.
  In: Translational and Experimental Medicine (Schuster D, Powers W, eds), Lippincott Publishing, 2005
• Monahan PE, Jooss K, Sands MS
  Safety of adeno-associated virus gene therapy vectors: a current evaluation.
  Expert Opin Drug Saf 2002 May;1(1):79-91
• Sands MS
  Gene therapy for lysosomal storage diseases affecting the brain.
  In: Lysosomal Storage Diseases Affecting the Central Nervous System (Platt F, Walkley SU, eds), Oxford University Press, Oxford, UK, 2004
• Daly TM, Sands MS
  Gene therapy for lysosomal storage diseases.
  Expert Opin Investig Drugs 1998 Oct;7(10):1673-82
• Wolfe JH, Sands M
  Murine mucopolysaccharidosis type VII: a model system for somatic gene therapy of the central nervious system.
  In: Gene Transfer into Neurones, Towards Gene Therapy of Neurological Disorders (Lowenstein P, Enquist L, eds), J. Wiley & Sons Ltd., Essex, England, 1996, p. 263
• Bogenhagen DF, Sands M, McConkey GA
  Domains of the 5S RNA gene control region.
  16th Annual Steenbock Symposium (Reznikoff WS et al, eds), Madison, WI, 1986, p. 219
• Violante MR, Fischer HW, Mare KO, Bosmann, HB, Owunwanne A, Zack AG, Harmon P, Case K, Sands M
  Maximizing hepatic contrast enhancement with a particular contrast agent in computed tomography.
  Contrast Media in Computed Tomography, International Workshop, Berlin, 1981